Clinical Trials Directory

Trials / Completed

CompletedNCT04620616

Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by ENDS Consumers

A Randomized, Open-Label, Multi-Center, Cross-Over Study of Adult Electronic Nicotine Delivery Systems (ENDS) Consumers to Assess Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With RELX Infinity ENDS

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
29 (actual)
Sponsor
Cheerain HK Limited · Industry
Sex
All
Age
22 Years – 59 Years
Healthy volunteers
Accepted

Summary

This study is being conducted to evaluate nicotine uptake, the potential abuse liability, and puffing topography associated with the use of an electronic nicotine delivery system (ENDS) with tobacco- and menthol-flavored e-liquids in current ENDS consumers.

Conditions

Interventions

TypeNameDescription
OTHERRELX ENDS Tobacco FlavorAd libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
OTHERRELX ENDS Menthol FlavorAd libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
OTHERSubject Usual Brand ENDSAd libitum use of the usual brand product during 8-hour and 5-minute use sessions

Timeline

Start date
2020-09-11
Primary completion
2021-01-04
Completion
2021-01-14
First posted
2020-11-09
Last updated
2021-01-19

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04620616. Inclusion in this directory is not an endorsement.